Medical World News® Behind the Science: Experts Discuss Key Research for Pancreatic Cancer Awareness Month

Video

CancerNetwork® spoke with Allyson J. Ocean, MD, Diane M. Simeone, MD, Manuel Hidalgo Medina, MD, PhD, and Andrew E. Hendifar, MD, about their recent research into the treatment of pancreatic cancer.

November is Pancreatic Cancer Awareness month and a good time to reflect on recent advancements in care for patients with these difficult to treat tumors. Since pancreatic tumors rarely produce symptoms in earlier stages, patients typically present with disease that is in advanced stages when it is most difficult to control. Additionally, options for systemic therapies are limited.

In a Behind the Science segment of the Medical World News® broadcast, CancerNetwork® met with Allyson J. Ocean, MD, Diane M. Simeone, MD, Manuel Hidalgo Medina, MD, PhD, and Andrew E. Hendifar, MD, oncologists who specialize in the treatment of pancreatic cancer, to discuss recent research that has the potential to significantly impact care and ongoing trials that clinicians should be aware of.

For a closer look at each of the interviews, see our related articles:

Using Genetic Predispositions to Determine the Likelihood of Being Diagnosed With Pancreatic Cancer

Recent Videos
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Related Content